Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

Company Overview

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease. The company’s lead programs are advancing through preclinical and early clinical stages, with a focus on establishing proof of concept in relevant patient populations. Research collaborations and strategic partnerships support Tenaya’s efforts to accelerate development timelines and expand its scientific capabilities.

Tenaya operates primarily in the United States, where it maintains its main research and manufacturing facilities. The company also engages with regulatory authorities to shape the clinical development and eventual commercialization of its therapies. Its management team combines expertise in gene therapy, cardiovascular biology and biopharmaceutical development, positioning Tenaya to tackle the complex challenges of translating novel genetic medicines into practical treatments.

With a commitment to addressing unmet needs in cardiovascular health, Tenaya Therapeutics seeks to transform the treatment landscape for patients with inherited heart diseases. By integrating advanced vector engineering with a deep understanding of cardiac biology, the company strives to deliver breakthrough therapies that offer long‐lasting benefits and improved quality of life.

Key Stats

• Today's Range: $0.72 to $0.76
• 50-Day Range: $0.68 to $0.92
• 52-Week Range: $0.53 to $2.35
• Volume: 1.60 million shs
• Average Volume: 2.41 million shs
• Market Capitalization: $159.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Moderate Buy

Tenaya Therapeutics Stock Analysis - MarketRank™

Tenaya Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 406th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tenaya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Tenaya Therapeutics has a consensus price target of $4.00, representing about 444.1% upside from its current price of $0.74.

Amount of Analyst Coverage

Tenaya Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tenaya Therapeutics are expected to grow in the coming year, from ($0.42) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenaya Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenaya Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenaya Therapeutics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.78% of the float of Tenaya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenaya Therapeutics has a short interest ratio ("days to cover") of 7.42.

Change versus previous month

Short interest in Tenaya Therapeutics has recently decreased by 5.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenaya Therapeutics does not currently pay a dividend.

Dividend Growth

Tenaya Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Tenaya Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Tenaya Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 10 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

MarketBeat Follows

9 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,317.00 in company stock.

Percentage Held by Insiders

2.53% of the stock of Tenaya Therapeutics is held by insiders.

Percentage Held by Institutions

90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/29/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNYA
• CIK: 1858848
• Web: www.tenayatherapeutics.com
• Phone: 650-825-6990
• Fax: N/A
• Employees: 110
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Tenaya Therapeutics: $4.00
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +444.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$90.60 million
• Net Margins: N/A
• Pretax Margin: -36,891.11%
• Return on Equity: -80.56%
• Return on Assets: -65.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.75
• Quick Ratio: 5.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 217,000,000
• Free Float: 211,509,000
• Market Cap: $159.52 million
• Optionable: Optionable
• Beta: 2.83